Biosimilar etanercept market shares between Swedish counties ranged from 40% to 82% in 2017 even though prices are coordinated nationally.

The choice to use the biosimilar or the originator product depends on the extent of the rebated price difference, the attitude of key opinion leaders, local guidelines, and gainsharing arrangements.

Price differences between etanercept products seem to be limited and might not compensate for the increased workload of switching.